Leading the Charge in Oncology Research
Terns Pharmaceuticals, Inc. (NASDAQ: TERN), headquartered in Foster City, California, is making significant strides in the oncology sector. As a clinical-stage company, Terns is focused on transforming conventional biological insights into groundbreaking treatments that improve patient outcomes dramatically.
Terns Pharmaceuticals at the Jefferies Global Healthcare Conference
This year, Terns Pharmaceuticals will participate in the prestigious Jefferies Global Healthcare Conference, taking place in London. Scheduled for presentation on November 17, the company's senior management team is set to delve into their latest innovations and strategies aimed at advancing cancer treatment.
Details of the Presentation
The Terns team will present at 4:30 p.m. GMT. Attendees can look forward to insights about their lead program, TERN-701, which represents a new frontier in therapy for patients with chronic myeloid leukemia (CML). A live webcast of this presentation will be available on the Terns Pharmaceuticals investor relations online platform.
Webcast and Archive Access
After the initial presentation, Terns will also provide a replay of the webcast accessible through their official website for at least 30 days. This approach not only keeps investors informed but also highlights the commitment Terns has toward transparency and engagement with its shareholder base.
About TERN-701: A Potential Game Changer
At the forefront of Terns' research efforts is their highly selective allosteric BCR-ABL inhibitor, TERN-701. This drug is being positioned as a potentially best-in-class option, aimed at outpacing existing CML treatments with regard to efficacy, safety, and overall patient convenience. The developers at Terns are optimistic about its ability to transform patient care significantly.
The Vision of Terns Pharmaceuticals
Terns Pharmaceuticals believes in revolutionizing healthcare through innovative medicines. They are systematically examining established biological pathways and leveraging this knowledge to create more impactful therapeutic options. With an unwavering commitment to addressing unmet medical needs, their approach is as much about healing as it is about understanding diverse patient needs.
Future Outlook
As Terns Pharmaceuticals continues its journey in the oncology sphere, future milestones at upcoming conferences will likely emphasize the efficacy of their solutions and their promise to redefine standards in cancer care.
Contact Information for Terns Pharmaceuticals
Investors and media representatives interested in reaching out can connect with the company directly. For investor inquiries, please contact Justin Ng at investors@ternspharma.com. Media inquiries can be directed to Jenna Urban at media@ternspharma.com.
Frequently Asked Questions
What is Terns Pharmaceuticals mainly focused on?
Terns Pharmaceuticals is primarily focused on developing innovative oncology treatments to improve patient outcomes.
When will Terns present at the Jefferies Global Healthcare Conference?
Terns will present on November 17 at 4:30 p.m. GMT.
What is TERN-701?
TERN-701 is Terns Pharmaceuticals' lead program, a selective BCR-ABL inhibitor designed to treat CML.
Where can I watch the Terns presentation?
The presentation will be streamed live on the Terns Pharmaceuticals investor relations page.
How can I contact Terns Pharmaceuticals?
You can reach Terns Pharmaceuticals through email at investors@ternspharma.com for investor queries and media@ternspharma.com for media-related inquiries.
